Saroglitazar, a novel PPAR α / γ agonist with predominant PPAR α activity, shows lipid‐lowering and insulin‐sensitizing effects in preclinical models
Author:
Affiliation:
1. Zydus Research Centre Cadila Healthcare Limited Sarkhej‐Bavla N.H. No. 8A, Moriya Ahmedabad 382 213 Gujarat India
2. National Institute for Research in Reproductive Health Parel Mumbai India
Funder
Cadila Healthcare Limited
Publisher
Wiley
Subject
General Pharmacology, Toxicology and Pharmaceutics,Neurology
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1002/prp2.136
Reference43 articles.
1. Magnitude of dyslipedemia and its association with micro and macro vascular complications in type 2 diabetes: A hospital based study from Bikaner (Northwest India)
2. Characterization of the Species-Specificity of Peroxisome Proliferators in Rat and Human Hepatocytes
3. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.
4. PPAR dual agonists: are they opening Pandora's box? Pharmacological research;Balakumar P;J Ital Pharmacol Soc,2007
5. Rosiglitazone
Cited by 81 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Organosulfur Compounds, S‐Allyl‐L‐Cysteine and S‐Ethyl‐L‐Cysteine, Target PCSK‐9/LDL‐R‐Axis to Ameliorate Cardiovascular, Hepatic, and Metabolic Changes in High Carbohydrate and High Fat Diet‐Induced Metabolic Syndrome in Rats;Phytotherapy Research;2024-09-03
2. A Prospective Randomised Comparative Four-arm Intervention Study of Efficacy and Safety of Saroglitazar and Vitamin E in Patients With Non-alcoholic Fatty Liver Disease (NAFLD)/Non-alcoholic Steatohepatitis (NASH)-SVIN TRIAL;Journal of Clinical and Experimental Hepatology;2024-09
3. Deciphering the molecular pathways of saroglitazar: A dual PPAR α/γ agonist for managing metabolic NAFLD;Metabolism;2024-06
4. Optimal drug regimens for improving ALP biochemical levels in patients with primary biliary cholangitis refractory to UDCA: a systematic review and Bayesian network meta-analysis;Systematic Reviews;2024-01-29
5. Saroglitazar, a Dual PPAR α/γ Agonist, Improves Atherogenic Dyslipidemia in Patients With Non-Cirrhotic Nonalcoholic Fatty Liver Disease: A Pooled Analysis;Clinical Gastroenterology and Hepatology;2023-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3